Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Neutral
Key Numbers
Market Cap
$35B
P/E
55
Revenue Growth
+15.0%
Gross Margin
N/A
ROE
N/A
About Veeva Systems
As a mid-cap healthcare company trading on the NYSE, Veeva Systems has established itself, benefiting from biotech and genomics tailwinds in its peripheral business lines. Cloud platform for life sciences companies managing clinical trials and compliance. Valued at 55x trailing earnings with a $35B market capitalization, Veeva Systems has delivered healthy growth momentum with revenue moving +15% over the past year.
Expert Coverage
Unlock Full VEEV Analysis
Expert analysis and coverage for Veeva Systems
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-06-30
More in Biotech & Genomics
BEAM
Beam Therapeutics
90
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%RXRX
Recursion Pharmaceuticals
88
True North
Pure Play
AI-driven drug discovery platform using machine learning to decode biology at scale.
NASDAQ
MCap $4BRev +55%